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Abstract:  We hereby describe the satisfactory evolution of rituximab treatment in two patients with Wegener’s 
granulomatosis (WG). Rituximab was indicated for refractoriness to standard treatment in one case and life-threatening 
myelotoxicity due to alkylating agents in the other. A brief review of previous experience with the use of rituximab in the 
treatment of WG is presented. 
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INTRODUCTION 
  Wegener’s granulomatosis (WG) is a granulomatous 
inflammation of the upper and lower respiratory tracts, with 
necrotizing vasculitis affecting small and medium-sized 
blood vessels and, frequently, necrotizing glomerulonephritis 
[1]. The introduction of glucocorticoid and 
cyclophosphamide treatment thirty years ago [2] represented 
a major step forward in the management of this disease, 
which had been almost invariably fatal until then. 
Nonetheless, treatment for WG is by no means fully 
satisfactory. As many as 25% of patients treated with 
alkylating agents or methotrexate do not achieve complete 
remission [3-5]. In addition, recurrence rates are between 
15% and 45% [6, 7], and between 20% and 50% of patients 
develop treatment related severe adverse effects [3, 5]. For 
all these reasons, research into the treatment of WG is still 
ongoing and many treatment protocols have been tested in 
attempts to reduce the toxicity associated with the prolonged 
use of alkylating agents [5, 8, 9]. 
  Rituximab is a chimeric monoclonal anti-CD20 antibody 
which achieves a selective, prolonged depletion of B 
lymphocytes. Mainly used for the treatment of B-cell 
lymphomas, rituximab has recently been used as salvage 
therapy in the treatment of various refractory autoimmune 
diseases [10]. Experience with rituximab in WG is limited to 
short series of patients, and the results have been variable 
[11-25]. 
  Recently, we have attended two patients with WG in 
whom rituximab was administrated as rescue medication for  
refractoriness to standard treatment in one case and life-
threatening myelotoxicity due to alkylating agents in the 
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other. Here we describe the striking response obtained in 
both cases. 
CLINICAL OBSERVATIONS 
 Case 1 
  A 43-year old male, smoker of 20 cig/day, was diagnosed 
of WG in March 1999 due to weight loss, weakness, mild 
fever, arthralgias, symptoms of nasal obstruction, 
hemoptysis with bilateral cavitated pulmonary infiltrates, 
and positive anti-proteinase 3 (anti-PR3) antibodies. Treated 
with prednisone (1mg/kg/day) and oral cyclophosphamide 
(2mg/kg/day) the patient gradually recovered, although the 
immunosuppressive treatment was prolonged for 18 months 
due to epistaxis, persistently high analytical inflammatory 
parameters and high anti-PR3 levels. After this period the 
patient was switched to azathioprine and low dose of 
steroids, achieving a sustained remission. 
  In May 2004, epistaxis reappeared, along with 
monoarthritis of the ankle, a 4-cm pulmonary nodule in the 
right lower lobe (Fig. 1A) and high anti-PR3 levels. 
Spirometry showed a mild obstructive pattern (FEV1 74%), 
and arterial gasometry on room air revealed a mild 
hypoxemia. Fiberbronchoscopy with cytologic examination 
of the bronchoaspirate and a transthoracic puncture of the 
pulmonary nodule were performed, only revealing necrotic 
tissue. Higher doses of prednisone along with azathioprine 
were prescribed. Given the progression of the pulmonary 
nodule in an active smoker, a lobectomy of the right inferior 
lobe was finally performed, which confirmed the presence of 
necrotizing vasculitis consistent with the diagnosis of WG. 
After surgery the patient presented a severe flare of the 
disease with the appearance of multiple lung cavities (Fig. 
1B) and diplopia due to a sixth cranial nerve palsy. 
Meningeal thickening consistent with pachymeningitis was 
found in a Magnetic Ressonance Imaging (MRI).   
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Fig. (1). (A) Observe a solitary lung nodule in the right lower lobe (GW was confirmed by surgical ressection). (B) Multiple cavitated lung 
nodules. (C1, C2) These chest X-ray and CT images show the progression of the cavitary lesions in spite of the immunosuppressive and 
antibiotic therapies. (D1, D2) Observe the radiological remission after rituximab administration. 96    The Open Respiratory Medicine Journal, 2009, Volume 3  Oristrell et al. 
Intravenous cyclophosphamide pulse (3 pulses of 500mg/m
2 
per month), bolus of 6-methylprednisolone (1g per day 
during three consecutive days), intravenous immunoglo-
bulins (400mg/Kg daily during 5 consecutive days) and oral 
mycophenolate (1g bid) were sequentially administrated 
without success. In February 2005, due to the persistence of 
constitutional symptoms and hemoptysis, infliximab was 
started obtaining a partial clinical and radiological response. 
However, the drug had to be withdrawn three months later as 
a result of severe abscessification of the lung cavities which 
resolved after a long course of parenteral antibiotic 
treatment. 
  One year later, in Novembre 2006, the patient presented a 
new flare of WG with asthenia, enlargement of lung cavities 
(Fig. 1C), arthralgia, prolonged fever, nodular skin lesions in 
the lower limbs and appearance of a mononeuritis of the 
right common peroneal nerve in spite of the patient was 
receiving maintenance treatment with mycophenolate 
(1g/12h) and prednisone (25mg/d). The patient was treated 
with four weekly infusions of rituximab (375mg/m2) 
together with mycophenolate (1g bid) and prednisone 
(40mg/d). 
  The patient’s response was striking, both clinically and 
radiologically (Fig. 1D). The analytical inflammatory and 
immunological parameters also showed a dramatic 
improvement (Table 1). Twenty-eight months later the 
patient remains in complete remission, with a notable 
reduction of the lung cavities, anti-PR3 antibodies remain 
below 10 U/ml, and levels of circulating B lymphocytes 
(CD19) are below 10 cells/L. The prednisone dose has been 
progressively tapered to 5mg/day and is the only 
maintenance treatment the patient is presently receiving. 
Table 1.  Activity Markers in the Two Cases of WG, Before 
and After Rituximab Treatment 
 
Patient No. 1  Before  
Rituximab 
3 Months  
After Rituximab 
ESR (mm)  113  33 
CRP (mg/dl)  21,2  2,8 
Leukocyte count (*10
-9/l) 17,200  13,670 
Hemoblogin (g/l)  95  130 
Anti-PR3 (U/l)  45  6 
BVAS-WG 10  0 
Patient No. 2  Before  
Rituximab 
6 Months  
After Rituximab 
ESR (mm)  129  27 
CRP (mg/dl)  12,9  0,1 
Leukocyte count(*10
-9/l) 15,200  8,310 
Hemoblogin (g/l)  92  124 
Anti-PR3 (U/l)  22  8 
BVAS-WG 17  0 
ESR: Erithrocyte sedimentation rate; CRP: C-Reactive protein; Anti-PR3: Anti-
proteinase 3 antibodies; BVAS: Birmingham Vasculitis Activity Score – Wegener’s 
granulomatosis. 
 
 Case 2 
  A 73 year-old male was admitted in May 2007 for study 
of a pulmonary mass together with asthenia, anorexia, 6kg 
weight loss, mild fever, arthralgia, diffuse abdominal pain, 
bilateral hypoacusia, right-sided otalgia and cephalea. 
Physical examination revealed no additional data of interest. 
Chest X-ray revealed a pulmonary nodule in the right upper 
lobe and a cranial CT scan showed occupation of the left 
tympanic cavity compatible with otitis media. 
  The chest CT scan showed bilateral pulmonary nodules 
and infiltrates. Spirometry showed a mild mixed ventilatory 
impairment. Fiberbronchoscopy revealed a diffusely 
infiltrated tracheobronchial mucosa and a bronchial biopsy 
disclosed the presence of necrotizing granulomas with 
negative stains for acid-alcohol resistant bacilli. Analytical 
tests showed increased values of C-reactive protein and the 
presence of high-titer anti-PR3 antibodies. A diagnosis of 
WG was established and oral prednisone (1mg/Kg) and a 
unique bolus intravenous cyclophosphamide (750mg/m2) 
with cotrimoxazol prophylaxis were initiated. 
  In the following days he developed hemoptysis, bilateral 
pulmonary infiltrates and acute respiratory failure (Fig. 2A). 
A second fiberbronchoscopy showed a diffuse alveolar 
hemorrhage. The patient required orotracheal intubation and 
mechanical ventilation. In the following days, the patient 
presented abdominal pain in the left iliac fossa and 
developed peritoneal signs. An urgent laparotomy revealed a 
mesenteric ischemia and an intestinal perforation. The 
resection of the ileum, cecum and transverse colon was 
performed. Other complications that also developed were 
pancytopenia due to the cyclophosphamide treatment, 
respiratory infection with MRSA and multiresistant P. 
Aeruginosa, acute renal failure due to acute tubular necrosis 
requiring hemodialysis, and semi-invasive pulmonary 
aspergillosis that was effectively treated with voriconazol. 
  Due to the severity of the WG (with involvement of the 
lung and gut) and to the presence of active severe infection 
in a immunocompromised host, the patient was given 
rituximab (375mg/m2 per week x 4 weeks) with bolus of 6-
methylprednisolone (1g/d x 3) followed by 1mg/kg/day of 
oral prednisone. 
  At this point the vasculitis entered in clinical remission, 
with an important resolution of lung infiltrates (Fig. 2B) and 
reduction of the inflammatory markers, c-ANCA titers and 
BVAS-WG score (Table 1), although the patient required a 
prolonged hospitalization due to the opportunistic infections, 
a short intestine syndrome with nutritional problems, and 
muscular atrophy. 
  Twenty-two months after diagnosis the patient remains 
stable treated only with a daily prednisone dose of 5mg/d. 
Anti-PR3 antibodies remain below 10 U/ml and B 
lymphocyte counts in peripheral blood remain below 10 
cells/L. 
DISCUSSION 
  To date, rituximab has been used in WG as rescue 
medication in cases of refractory disease or in cases with a 
contraindication to cyclophosphamide. At the present 
moment there is no reliable evidence of the drug’s   
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Table 2.  Previous Reports on the Use of Rituximab in Wegener’s Granulomatosis* (In Chronologically Order) 
 
Author/Year Indication  No.  pts  Dose  Previous 
Treatment 
BVAS-GW  Results on 
ANCA Titer 
Response 
Rate 
Follow-Up 
(Months) 
Relapses 
Eriksson [12], 
2005 
Refractory/ 
relapsing disease 
7  375mg/m2/w x 
2-4 infusions 
Prd, Cyc, 
Aza, MMF 
Reduced  Unchanged  6 CR, 1PR  6-24   2/7 
Keogh [13], 2005 
Refractory 
disease or Cyc 
intolerance 
10  375mg/m2/w x 
4 infusions 
Prd, Cyc, 
MTX, MMF  
Reduced  Decreased  9 CR, 1 PR  10-42  2/10 
Omdal [14], 2005  Refractory/ 
relapsing disease 
3  375mg/m2/w x 
4 infusions 
Prd, Cyc, 
MTX, MMF, 
Aza 
NS  Decreased  3 CR  24   3/3 
Keogh [15], 2006 
Refractory 
disease or Cyc 
intolerance 
10  375mg/m2/w x 
4 infusions 
Prd, Cyc, 
Aza, MTX 
Reduced Decreased  10  CR  12  1/10 
Aries [16], 2006  Refractory 
disease 
8 375mg/m2/mth  Prd, Cyc, 
MTX, MMF 
Unchanged Unchanged 2 CR, 1 PR, 
5 failures 
NS 0/8 
Stasi [19], 2006  Refractory or 
relapsing disease  8  375mg/m2/w x 
4 infusions 
Prd, Cyc, 
Aza, MTX, 
CyA, Ig, 
cotrimoxazol 
Reduced Decreased  7 CR,  
1 PR  33 3/8 
Golbin [25], 2006  Refractory or Cyc 
contraindicated 
21  375mg/m2/w x 
2-4 infusions  
Prd NS  Unchanged  NS  19-70  7/21 
García [10], 2007  Severe WG  4  375mg/m2/w x4 
infusions 
Cyc, Prd  Unchanged  NS  1 PR, 
3 failures  
NS 1/4 
Henes [16], 2007  Refractory 
disease 
6  375mg/m2/w x 
4 infusions 
Prd, 
Leflunom 
Reduced Decreased  5 CR, 
1 PR 
12-21 1/6 
Tamura [17], 2007  Refractory 
disease 
2  375mg/m2/w x 
4 infusions 
Prd Reduced  Normalized  2  CR 6-13 1/2 
Brihaye [18], 2007  Refractory/ 
relapsing disease 
8  375mg/m2/w x 
4 infusions 
Prd, IS  
(not 
specified) 
Reduced NS 
3 CR,  
3 PR,  
2 failures 
NS 1/8 
Sánchez-Cano 
[21], 2008 
Refractory 
disease/ Cyc 
contraindicated 
4  375mg/m2/w x 
4 infusions 
Prd, Cyc, 
MTX, Aza 
Reduced  Decreased  2 CR, 2 PR  8-26  3/4 
Sao [29], 2008 
Refractory 
disease or Cyc 
intolerance 
8  375mg/m2/w x 
4 infusions 
Prd, Cyc, 
MTX 
Reduced  Decreased  8  CR NS 5/8 
*Only reports of 2 or more cases. 
Prd: Prednisone; Cyc: Cyclophosphamide; Aza: Azathioprine; MTX: Methotrexate; MMF: Mycophenolate; CyA: Cyclosporine A; Ig: Immunoglobulins; Leflunom: leflunomide; 
NS: Not specified. CR: Complete response. PR: Partial response. 
(A)             ( B) 
          
Fig. (2). (A). Extensive lung infiltrates in a patient with WG. (B) After rituximab administration, lung infiltrates mainly disapeared and only 
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effectiveness in WG. About 100 cases of WG treated with 
rituximab have been reported in the medical literature, in 
general in small case series (Table 2) [10-25]. 
  Neither of our cases had kidney involvement, but both 
patients presented serious and life-threatening lung and 
systemic disease. The first case presented predominantly 
lung granulomatous and necrotizing disease refractory to 
multiple immunosuppressive treatments. The second patient 
presented a rapidly progressive vasculitis with pulmonary 
hemorrhage, intestinal infarction and complications caused 
by the administration of bolus cyclophosphamide which 
limited its subsequent use. 
  Our patients presented a rapid and effective response to 
rituximab treatment, as it has been described in several 
previous reports. We also observed a good response in our 
first patient, with a predominant granulomatous disease, 
although some authors have claimed that these patients were 
refractory to rituximab treatment [14, 16]. 
  Both patients remain well and remission-free 28 and 22 
months after rituximab infusion. Previous descriptions have 
shown a relapse rate of 30% (29/99) (Table 2), mainly 
throughout the first 12 months. Keogh and colleagues [15, 
25] have described that, commonly, relapses in their patients 
were preceded by a raising number of circulating B cells and 
an increase in the anti-PR3 antibodies. Our results are in 
agreement with these observations since both circulating B 
cells and anti-PR3 antibodies have remained low. 
  In conclusion, we believe that rituximab may be an 
effective alternative for patients with WG in whom 
conventional immunosuppressive agents have failed or have 
contraindications to be used. In the future, the results of 
several clinical trials currently underway [26-28] will shed 
more light on the role of rituximab in the treatment of WG. 
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